Caribou Biosciences initiated with a Buy at Clear Street

Clear Street initiated coverage of Caribou Biosciences (CRBU) with a Buy rating and $13 price target Caribou is developing a pipeline of off-the-shelf allogeneic CAR-T cell therapies, including lead asset vispa-cel, the analyst tells investors. Vispa-cel is preparing to enter a registrational Phase 3 study in second line or later large B-cell lymphoma, notes the analyst, whose model includes vispa-cel peak sales of $992M in 2040 and 30% odds of success as well as CB-011 peak sales of $734M in 2040 and 20% odds of success.